DRD2 and glioblastoma: To further assess the role of dopamine receptors in glioblastoma cell motility, the effects of the selective dopamine receptor D2 inhibitor L-741,626 and the selective dopamine receptor D4 inhibitor L-745,870 [31, 32] were determined.